Abciximab, heparin
The combination may increase the risk of bleeding
ACE inhibitors, heparin
Potassium-sparing diuretics potassium supplements or potassium-containing salt substitutes have been shown to increase the risk of hyperkalaemia when used concomitantly with ACE inhibitors.
ACE inhibitors, sodium heparin [2] ---> SmPC of [2] of eMC
Combined use of heparin with ACE inhibitors or angiotensin II antagonists may increase the risk of hyperkalaemia.
Acenocoumarol [1], heparin ---> SmPC of [1] of eMC
Drugs altering haemostasis may potentiate the anticoagulant activity and increase the risk of haemorrhage. The use concomitant is not recommended
Acetylsalicylic acid [1], heparin ---> SmPC of [1] of eMC
Increased risk of bleeding due to inhibited thrombocyte function, injury of the duodenal mucosa and displacement of oral anticoagulants from their plasma protein binding sites. The bleeding time should be monitored
Adrenaline, heparin
The tendency to bleed is increased during the treatment with anticoagulants and adrenaline
AIIRA, heparin ---> SmPC of [sodium heparin] of eMC
Combined use of heparin with ACE inhibitors or angiotensin II antagonists may increase the risk of hyperkalaemia.
AIIRA, sodium heparin [2] ---> SmPC of [2] of eMC
Combined use of heparin with ACE inhibitors or angiotensin II antagonists may increase the risk of hyperkalaemia.
Aliskiren [1], heparin ---> SmPC of [1] of EMA
Concomitant use of other agents affecting the RAAS, of NSAIDs or of agents that increase serum potassium levels may lead to increases in serum potassium.
Aliskiren/amlodipine [1], heparin ---> SmPC of [1] of EMA
Concomitant use of aliskiren/amlodipine and other agents that increase serum potassium levels may lead to increases in serum potassium. Caution is advisable.
Aliskiren/amlodipine/hydrochlorothiazide [1], heparin ---> SmPC of [1] of EMA
Concomitant use of aliskiren with other agents that increase serum potassium levels may lead to increases in serum potassium. If co-medication is considered necessary, caution is advisable.
Aliskiren/hydrochlorothiazide [1], heparin ---> SmPC of [1] of EMA
Concomitant use of aliskiren with other agents that increase serum potassium levels may lead to increases in serum potassium. If co-medication is considered necessary, caution is advisable.
Alteplase [1], low molecular weight heparins ---> SmPC of [1] of eMC
Increased risk of haemorrhage
Alteplase [1], unfractionated heparins ---> SmPC of [1] of eMC
Increased risk of haemorrhage
Anticoagulants, heparin ---> SmPC of [sodium heparin] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Anticoagulants, sodium heparin [2] ---> SmPC of [2] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Antifibrinolytics, heparin
The co-administration may weaken the effect of antifibrinolytic agent
Antihistamines, heparin
Possible decrease of anticoagulant effect of heparin
Antihistamines, sodium heparin
Possible decrease of anticoagulant effect of heparin
Antithrombin alfa [1], heparin ---> SmPC of [1] of EMA
Antithrombin replacement during administration of anticoagulants that potentiate the anticoagulant activity of antithrombin (e.g., heparin, low molecular weight heparin), may increase the risk of bleeding.
Antithrombin alfa [1], low molecular weight heparins ---> SmPC of [1] of EMA
Antithrombin replacement during administration of anticoagulants that potentiate the anticoagulant activity of antithrombin (e.g., heparin, low molecular weight heparin), may increase the risk of bleeding.
Antithrombin III, heparin
Increased effect of antithrombin III
Apixaban [1], heparin ---> SmPC of [1] of EMA
Due to an increased bleeding risk, concomitant treatment of apixaban with any other anticoagulants is contraindicated
Apixaban [1], low molecular weight heparins ---> SmPC of [1] of EMA
Due to an increased bleeding risk, concomitant treatment of apixaban with any other anticoagulants is contraindicated
Apixaban [1], unfractionated heparins ---> SmPC of [1] of EMA
Due to an increased bleeding risk, concomitant treatment of apixaban with any other anticoagulants is contraindicated
Articaine/epinephrine, heparin
There is an increase in the tendency to bleed during the treatment with anticoagulant medicinal products
Asparaginase [1], heparin ---> SmPC of [1] of EMA
Concomitant use of glucocorticoids and/ or anticoagulants with asparaginase may increase the risk of a change in coagulation parameters (see section 4.4). This can promote tendency to bleeding (anticoagulants) or thrombosis (glucocorticoids).
Azilsartan medoxomil [1], heparin ---> SmPC of [1] of EMA
Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products (e.g. heparin) may increase potassium levels. Monitoring of serum potassium should be undertaken as appropriate
Benazepril, heparin
Potassium-sparing diuretics potassium supplements or potassium-containing salt substitutes have been shown to increase the risk of hyperkalaemia when used concomitantly with ACE inhibitors.
Benzodiazepines, heparin ---> SmPC of [sodium heparin] of eMC
Heparin may increase the effect of benzodiazepines
Benzodiazepines, sodium heparin
Heparin may increase the effect of benzodiazepines
Bivalirudin [1], heparin ---> SmPC of [1] of EMA
Combined use of anti-coagulant medicinal products can be expected to increase the risk of bleeding.
Breast-feeding, heparin
Heparin does not pass into the mother's milk
Breast-feeding, sodium heparin [2] ---> SmPC of [2] of eMC
Heparin is not excreted in breast milk.
Bumadizone, heparin
It is recommended a regular control of the prothrombin time
Bupivacaine, heparin
Increased bleeding tendency
Candesartan cilexetil [1], heparin ---> SmPC of [1] of eMC
Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products (e.g. heparin) may increase potassium levels.
Candesartan [1], heparin ---> SmPC of [1] of eMC
Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products (e.g. heparin) may increase potassium levels.
Cangrelor [1], heparin ---> SmPC of [1] of EMA
No pharmacokinetic or pharmacodynamic interaction with cangrelor was observed in an interaction study with acetylsalicylic acid, heparin, or nitroglycerin.
Cangrelor [1], low molecular weight heparins ---> SmPC of [1] of EMA
In clinical studies, cangrelor has been co-administered with bivalirudin, low molecular weight heparin, fondaparinux, and GP IIb/IIIa inhibitors with no apparent effect upon the pharmacokinetics or pharmacodynamics of cangrelor.
Captopril, heparin
The co-administration may increase the potassium level
Cefamandol, heparin ---> SmPC of [sodium heparin] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system.
Cefamandol, sodium heparin [2] ---> SmPC of [2] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Cefoperazone, heparin ---> SmPC of [sodium heparin] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system.
Cefoperazone, sodium heparin [2] ---> SmPC of [2] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Cilazapril [1], heparin ---> SmPC of [1] of eMC
Potassium sparing diuretics, potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
Clopidogrel [1], heparin ---> SmPC of [1] of EMA
Co-administration of heparin had no effect on the inhibition of platelet aggregation induced by clopidogrel. A pharmacodynamic interaction between clopidogrel and heparin is possible, leading to increased risk of bleeding.
Clopidogrel/acetylsalicylic acid [1], heparin ---> SmPC of [1] of EMA
A pharmacodynamic interaction between clopidogrel/acetylsalicylic acid and heparin is possible, leading to increased risk of bleeding. Caution is recommended
Colchicine, heparin
The co-administration may decrease the effect of colchicine and/or increase its toxicity
Corticosteroids, heparin ---> SmPC of [sodium heparin] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system.
Dabigatran etexilate [1], heparin ---> SmPC of [1] of EMA
The co-administration may increase the risk of bleeding
Dabigatran etexilate [1], low molecular weight heparins ---> SmPC of [1] of EMA
Concomitant treatment of dabigatran with any other anticoagulants is contraindicated, except under specific circumstances of switching anticoagulant therapy or when UFH is given at doses necessary to maintain an open central venous or arterial catheter
Dabigatran etexilate [1], unfractionated heparins ---> SmPC of [1] of EMA
Concomitant treatment of dabigatran with any other anticoagulants is contraindicated, except under specific circumstances of switching anticoagulant therapy or when UFH is given at doses necessary to maintain an open central venous or arterial catheter
Dabigatran, low molecular weight heparins
The co-administration may increase the risk of bleeding
Dabigatran, unfractionated heparins [2] ---> SmPC of [2] of EMA
Concomitant use not recommended. UFH can be administered at doses necessary to maintain a catheter patent
Daunorubicin, heparin
Not mixing in the same infusion
Defibrotide [1], heparin ---> SmPC of [1] of EMA
Concomitant systemic anticoagulant therapy, except for routine maintenance or reopening of central venous line, requires careful monitoring.
Desirudin [1], low molecular weight heparins ---> SmPC of [1] of EMA
During prophylaxis, concomitant use is not recommended. Additive effects in the activated partial thromboplastin time
Desirudin [1], unfractionated heparins ---> SmPC of [1] of EMA
During prophylaxis, concomitant use is not recommended. Additive effects in the activated partial thromboplastin time
Dexibuprofen [1], heparin ---> SmPC of [1] of eMC
As with other NSAIDs, concomitant treatment with drugs increasing potassium plasma levels, may be associated with increased serum potassium levels and may increase the risk of renal failure
Dexketoprofen [1], heparin ---> SmPC of [1] of eMC
Increased risk of haemorrhage (due to the inhibition of platelet function and damage to the gastroduodenal mucosa).
Dextran, heparin ---> SmPC of [sodium heparin] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Dextran, sodium heparin [2] ---> SmPC of [2] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Digital glycosides, heparin calcium
Possible decrease of anticoagulant effect of heparin
Digital glycosides, sodium heparin
Possible decrease of anticoagulant effect of heparin
Doxorubicine [1], heparin ---> SmPC of [1] of eMC
Doxorubicin binds to heparin. Precipitations and loss of action of both substances are therefore possible.
Drotrecogin alfa [1], heparin ---> SmPC of [1] of EMA
The concurrent heparin therapy ≥ 15 International Units/kg/hr is contraindicated
Epoprostenol, heparin ---> SmPC of [sodium heparin] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Epoprostenol, sodium heparin [2] ---> SmPC of [2] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Eprosartan [1], heparin ---> SmPC of [1] of eMC
Concomitant use of eprosartan with K-sparing diuretics, K-supplements, salt substitutes containing potassium or other drugs that may increase serum potassium levels (e.g. heparin) may lead to increase in serum potassium.
Felodipine/ramipril [1], heparin ---> SmPC of [1] of eMC
Rise in serum potassium concentration possible.
Fibrinolytics, heparin ---> SmPC of [sodium heparin] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Fibrinolytics, sodium heparin [2] ---> SmPC of [2] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Fondaparinux [1], heparin ---> SmPC of [1] of EMA
Agents that may enhance the risk of haemorrhage should not be administered concomitantly with fondaparinux.
Fondaparinux [1], low molecular weight heparins ---> SmPC of [1] of EMA
Agents that may enhance the risk of haemorrhage should not be administered concomitantly with fondaparinux.
Fosinopril [1], heparin ---> SmPC of [1] of eMC
Potassium-sparing diuretics potassium supplements or potassium-containing salt substitutes have been shown to increase the risk of hyperkalaemia when used concomitantly with ACE inhibitors.
Glibenclamide [1], heparin ---> SmPC of [1] of EMA
Potentiation of the blood-glucose lowering
Glucocorticoids, heparin ---> SmPC of [sodium heparin] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Glucocorticoids, sodium heparin [2] ---> SmPC of [2] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Glycerol trinitrate [1], heparin ---> SmPC of [1] of eMC
There is evidence that systemic nitrates may interfere with the anticoagulant effects of heparin.
GP IIb/IIIa inhibitors, heparin ---> SmPC of [sodium heparin] of eMC
It is considered unsafe to take NSAIDs in combination with anticoagulants due to increased risk of bleeding. If coadministration is unavoidable, patient should be closely monitored.
Heparin calcium, medronic acid
Increased enrichment of radiotracer outside of bones
Heparin calcium, mineralocorticoids
The co-administration may cause a mutual enhancement of the anticoagulant effect
Heparin calcium, NSAID ---> SmPC of [sodium heparin] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Heparin calcium, pregnancy
Heparin calcium should be only administered during the pregnancy as absolute indication
Heparin calcium, protamine
The i.v. injection of protamine abolish fast the heparin effect
Heparin calcium, salicylates
The co-administration may cause a mutual enhancement of the anticoagulant effect
Heparin calcium, tetracyclines
Possible decrease of anticoagulant effect of heparin
Heparin, hyaluronidase
Inhibition of hyaluronidase
Heparin, hyperkalemia ---> SmPC of [sodium heparin] of eMC
Medicinal products that increase potassium plasma concentrations, like heparine, should only be used under especially careful medical supervision
Heparin, iloprost [2] ---> SmPC of [2] of EMA
Since iloprost inhibits platelet function its use with anticoagulants or other inhibitors of platelet aggregation may increase the risk of bleeding. A careful monitoring of the patients is recommended.
Heparin, imatinib [2] ---> SmPC of [2] of EMA
Because of known increased risks of bleeding in conjunction with the use of imatinib (e.g. haemorrhage), patients who require anticoagulation should receive low-molecular-weight or standard heparin, instead of coumarin derivatives such as warfarin.
Heparin, irbesartan [2] ---> SmPC of [2] of EMA
Concomitant use of irbesartan und potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels is not recommended
Heparin, irbesartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA
Possible increase of potassium plasma concentrations. Concomitant use not recommended
Heparin, kebuzone
The co-administration may enhance the effects and increase the bleeding risk
Heparin, ketoprofen [2] ---> SmPC of [2] of eMC
Increased risk of bleeding
Heparin, lornoxicam
NSAIDs may increase the risk of epidural or spinal hematoma when concomitantly administered with heparins in epidural or spinal anaesthesia
Heparin, losartan [2] ---> SmPC of [2] of eMC
Concomitant use of other drugs which retain potassium or may increase potassium levels, potassium supplements or salt substitutes containing potassium may lead to increases in serum potassium. Co-medication is not advisable.
Heparin, macrosalb
Pharmacological interactions may occur
Heparin, melagatran
The co-administration may significantly increase the bleeding risk
Heparin, meloxicam
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system.
Heparin, methylprednisolone
Decreased or increased heparin effect
Heparin, mezlocillin
The coagulation parameters should be controlled more regularly and often in the concomitant use
Heparin, moexipril
Potassium-sparing diuretics potassium supplements or potassium-containing salt substitutes have been shown to increase the risk of hyperkalaemia when used concomitantly with ACE inhibitors.
Heparin, naproxen/esomeprazole [2] ---> SmPC of [2] of eMC
NSAIDs may enhance the effects of heparins
Heparin, nitroglycerine [2] ---> SmPC of [2] of eMC
There is evidence that systemic nitrates may interfere with the anticoagulant effects of heparin.
Heparin, NSAID ---> SmPC of [sodium heparin] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Heparin, olmesartan
Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other drugs that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium.
Heparin, olmesartan medoxomil [2] ---> SmPC of [2] of eMC
Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other drugs that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium.
Heparin, olmesartan medoxomil/amlodipine [2] ---> SmPC of [2] of eMC
Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other drugs that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium.
Heparin, oral anticoagulants ---> SmPC of [sodium heparin] of eMC
It is considered unsafe to take NSAIDs in combination with anticoagulants due to increased risk of bleeding. If coadministration is unavoidable, patient should be closely monitored.
Heparin, oral antidiabetics ---> SmPC of [sodium heparin] of eMC
Heparin may increase the effect of oral antidiabetic agents
Heparin, organic nitrates ---> SmPC of [nitroglycerine] of eMC
There is evidence that systemic nitrates may interfere with the anticoagulant effects of heparin.
Heparin, palifermin [2] ---> SmPC of [2] of EMA
Heparins should be used with care in patients receiving palifermin and appropriate blood coagulation tests should be carried out to monitor their treatment.
Heparin, pegaspargase [2] ---> SmPC of [2] of EMA
The use of Oncaspar can lead to fluctuating coagulation factors. This can promote the tendency to bleeding and/or thrombosis. Caution is therefore needed when anticoagulants are given concomitantly.
Heparin, penicillins
High-dose treatment with penicillins enhances the effect of heparin
Heparin, pentosan polysulfate
Mutual enhancement of anticoagulant effect
Heparin, pentosan polysulfate sodium [2] ---> SmPC of [2] of EMA
Patients who are concomitantly treated should be evaluated for any haemorrhagic event in order to adapt the dose if needed
Heparin, pentosan sulfate
Mutual enhancement of anticoagulant effect
Heparin, perindopril [2] ---> SmPC of [2] of eMC
The combination of these drugs increases the risk of hyperkalaemia.
Heparin, phenindione
The co-administration is not recommended since it may increase the intensity of bleedings
Heparin, piperacillin
During simultaneous administration of heparin, oral anticoagulants and other drugs that may affect the blood coagulation system, appropriate coagulation tests should be performed more frequently and monitored regularly.
Heparin, piperacillin/tazobactam [2] ---> SmPC of [2] of eMC
During simultaneous administration of heparin, oral anticoagulants and other drugs that may affect the blood coagulation system, appropriate coagulation tests should be performed more frequently and monitored regularly.
Heparin, platelet aggregation inhibitors ---> SmPC of [sodium heparin] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system.
Heparin, potassium chloride ---> SmPC of [sodium heparin] of eMC
Medicinal products that increase potassium plasma concentrations, like heparine, should only be used under especially careful medical supervision
Heparin, prasugrel [2] ---> SmPC of [2] of EMA
Both medicinal products can be administered concomitantly. An increased risk of bleeding is possible when prasugrel is coadministered with heparin.
Heparin, prednisolone
The anticoagulant effect may increase or decrease
Heparin, pregnancy
Should not be used in pregnant women unless strictly necessary
Heparin, procaine
Enhancement of an existent haemorrhagic diathesis
Heparin, proglumetacine
The NSAID may enhance the effects of anticoagulant agent
Heparin, propranolol ---> SmPC of [sodium heparin] of eMC
Enhanced propranolol effect due to displacement from protein binding sites
Heparin, protamine
The i.v. injection of protamine abolish fast the heparin effect
Heparin, ramipril [2] ---> SmPC of [2] of eMC
Hyperkalaemia may occur, therefore close monitoring of serum potassium is required. Caution is recommended
Heparin, reteplase [2] ---> SmPC of [2] of EMA
Caution should be employed when used reteplase with other medicinal products affecting haemostasis
Heparin, retinol
Concomitant use of parenteral anticoagulants with vitamin A may increase the anticoagulant effect and the risk of bleeding
Heparin, sacubitril/valsartan [2] ---> SmPC of [2] of EMA
Concomitant use of potassium-sparing diuretics, mineralocorticoid antagonists, potassium supplements, salt substitutes containing potassium or other agents (such as heparin) may lead to increases in serum potassium, and to increases in serum creatinine.
Heparin, salicylates ---> SmPC of [sodium heparin] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Heparin, selexipag [2] ---> SmPC of [2] of EMA
Selexipag is an inhibitor of platelet aggregation in vitro. In the Phase 3 placebo-controlled study in patients with PAH, no increased risk of bleeding was detected with selexipag compared to placebo
Heparin, spirapril
Increased risk of hyperkalemia, particularly in renal failure
Heparin, spironolactone
The concomitant use of spironolactone and heparin may cause hypercaliemia
Heparin, streptokinase [2] ---> SmPC of [2] of eMC
There is an increased risk of haemorrhage in patients who are receiving or who have recently been treated with anticoagulants or drugs which inhibit platelet formation or function
Heparin, sulfonylureas
Heparin may increase the effect of oral antidiabetic agents
Heparin, telmisartan [2] ---> SmPC of [2] of EMA
As with other medicinal products acting on the renin-angiotensin-aldosterone system, telmisartan may provoke hyperkalaemia. The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia
Heparin, telmisartan/amlodipine ---> SmPC of [telmisartan] of EMA
As with other medicinal products acting on the renin-angiotensin-aldosterone system, telmisartan may provoke hyperkalaemia. The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia
Heparin, thrombolytics ---> SmPC of [sodium heparin] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Heparin, tiaprofenic acid
It is considered unsafe to take NSAIDs in combination with anticoagulants due to increased risk of bleeding. If coadministration is unavoidable, patient should be closely monitored.
Heparin, ticagrelor [2] ---> SmPC of [2] of EMA
Co-administration of ticagrelor with heparin did not have any effect on ADP-induced platelet aggregation. If clinically indicated, medicinal products that alter haemostasis should be used with caution in combination with ticagrelor
Heparin, ticlopidine
Increased bleeding risk (combination of the anticoagulant and platelet aggregation inhibitor effect)
Heparin, tirofiban [2] ---> SmPC of [2] of eMC
The use of platelet aggregation inhibitors with heparin increases the risk of bleeding
Heparin, tolbutamide
Increased hypoglycaemic effects have occurred or might be expected
Heparin, triflusal
Triflusal enhances the effect of anticoagulant agent
Heparin, urokinase [2] ---> SmPC of [2] of eMC
Oral anticoagulants or heparin may increase the risk of haemorrhage and should not be used concomitantly with urokinase.
Heparin, valsartan [2] ---> SmPC of [2] of eMC
Concomitant use with of valsartan with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other agents that may increase potassium levels (heparin, etc.) is not recommended.
Heparin, vitamin A
Concomitant use of parenteral anticoagulants with vitamin A may increase the anticoagulant effect and the risk of bleeding
Heparin, vitamin K antagonists ---> SmPC of [sodium heparin] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Heparin, vorapaxar [2] ---> SmPC of [2] of EMA
In patients treated with vorapaxar the concomitant use of heparin (including LMWH) might be associated with an increased risk of bleeding and caution is advised.
Heparin, ximelagatran
The co-administration may significantly increase the bleeding risk
Hyperkalemia, sodium heparin
Medicinal products that increase potassium plasma concentrations, like heparine, should only be used under especially careful medical supervision
Low molecular weight heparins, melagatran
The co-administration may significantly increase the bleeding risk
Low molecular weight heparins, olsalazine
The coadministration of salicylates and low molecular weight heparins may result in an increased risk of bleeding, more specifically hematomas following neuraxial anesthesia.
Low molecular weight heparins, phenprocoumon
Enhancement of phenprocoumon effect and increased bleeding risk with the concomitant administration of other anticoagulant drugs
Low molecular weight heparins, prasugrel [2] ---> SmPC of [2] of EMA
Efient has been co-administered in the phase 3 clinical trial with low molecular weight heparin, bivalirudin, and GP IIb/IIIa inhibitors without evidence of clinically significant adverse interactions.
Low molecular weight heparins, reteplase [2] ---> SmPC of [2] of EMA
Caution should be employed when used reteplase with other medicinal products affecting haemostasis
Low molecular weight heparins, rivaroxaban [2] ---> SmPC of [2] of EMA
Concomitant treatment with any other anticoagulants is contraindicated, except under specific circumstances of switching anticoagulant therapy or when UFH is given at doses necessary to maintain an open central venous or arterial catheter.
Low molecular weight heparins, salicylates
The coadministration of salicylates and low molecular weight heparins may result in an increased risk of bleeding, more specifically hematomas following neuraxial anesthesia.
Low molecular weight heparins, spironolactone
The concomitant use of spironolactone and heparin may cause hypercaliemia
Low molecular weight heparins, tenecteplase [2] ---> SmPC of [2] of EMA
Medicinal products that affect coagulation or those that alter platelet function may increase the risk of bleeding prior to, during or after tenecteplase therapy.
Low molecular weight heparins, ximelagatran
The co-administration may significantly increase the bleeding risk
Melagatran, unfractionated heparins
The co-administration may significantly increase the bleeding risk
Mineralocorticoids, sodium heparin
The co-administration may cause a mutual enhancement of the anticoagulant effect
Nitroglycerine, sodium heparin
The anticoagulant effect of heparin may decrease in patients treated with iv nitroglycerin
NSAID, sodium heparin [2] ---> SmPC of [2] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Oral antidiabetics, sodium heparin
Heparin may increase the effect of oral antidiabetic agents
Oritavancin [1], sodium heparin ---> SmPC of [1] of EMA
Use of intravenous unfractionated heparin sodium is contraindicated for 120 hours after oritavancin administration
Phenprocoumon, unfractionated heparins
Enhancement of phenprocoumon effect and increased bleeding risk with the concomitant administration of other anticoagulant drugs
Platelet aggregation inhibitors, sodium heparin [2] ---> SmPC of [2] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Potassium citrate/potassium hydrogen carbonate [1], sodium heparin ---> SmPC of [1] of EMA
Concomitant use of Sibnayal with medicinal products that may increase potassium levels or induce hyperkalaemia necessitates monitoring of potassium plasma levels
Pregnancy, sodium heparin [2] ---> SmPC of [2] of eMC
Because of the known haemorrhagic effect, heparin should be used with caution in pregnant women and only if the benefits outweigh the risks according to the physician's judgement.
Propranolol, sodium heparin
Enhanced propranolol effect due to displacement from protein binding sites
Protamine, sodium heparin
The i.v. injection of protamine abolish fast the heparin effect
Rivaroxaban [1], unfractionated heparins ---> SmPC of [1] of EMA
Concomitant treatment with any other anticoagulants is contraindicated, except under specific circumstances of switching anticoagulant therapy or when UFH is given at doses necessary to maintain an open central venous or arterial catheter.
Sodium heparin [1], sulfonylureas ---> SmPC of [1] of eMC
Heparin may increase the effect of oral antidiabetic agents
Sodium heparin [1], thrombolytics ---> SmPC of [1] of eMC
The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system
Sodium heparin, telmisartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA
Medicinal products that may increase potassium levels or induce hyperkalaemia: Concomitant use of the these medicinal products may lead to increases in serum potassium and is, therefore, not recommended
Sodium heparin, tetracyclines
Possible decrease of anticoagulant effect of heparin
Sugammadex [1], unfractionated heparins ---> SmPC of [1] of EMA
In in vitro experiments a aPTT and PT prolongation
Unfractionated heparins, ximelagatran
The co-administration may significantly increase the bleeding risk